Table 1 Demographic and disease profile
From: Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer
Age (median––range) | 66 (23–83) |
Gender | Male 52 (71%) Female 21 (29%) |
Management | |
Surgical treatment | 65 (89%) |
Resection | 55 |
Pancreaticoduodenectomy | 47 |
Distal pancreatectomy + splenectomy | 5 |
Total pancreatectomy | 2 |
Central pancreatectomy | 1 |
No resection | 10 |
Palliative procedures | 8 |
Intraoperative biopsy only | 2 |
No surgical treatment | 8 (11%) |
Histology of resected specimen | |
Malignant | 46 (63%) |
Pancreatic ductal adenocarcinoma | 18 |
Ampullary adenocarcinoma | 15 |
Neuroendocrine tumor | 6 |
Distal bile duct cholangiocarcinoma | 4 |
Duodenal adenocarcinoma | 2 |
Pancreatic adenosquamous carcinoma | 1 |
Benign | 9 (12%) |
Groove pancreatitis | 2 |
Chronic pancreatitis | 2 |
Ampullary tubulovillous adenoma | 2 |
Mucinous neoplasm | 1 |
Serous cystadenoma | 1 |
Solid pseudopapillary tumor | 1 |
Histology/cytology from biopsy | 18 (25%) |
Pancreatic ductal/ampullary adenocarcinoma | 8 |
Neuroendocrine tumor | 1 |
Adenocarcinoma (frozen section) | 5 |
Histology not confirmed (clinical/radiological diagnosis) | 4 |
Cancer differentiationa | |
Well and moderately differentiated | 34 |
Poorly differentiated | 16 |
Resection marginb | |
R0 | 18 |
R1 | 28 |